Integrin alpha 4 beta 1

Integrin alpha 4 beta 1

Integrin alpha 4 beta 1 Informations sur la molécule

Molecule Name
Integrin alpha-4/beta-1
Alias de la molécule
Integrin alpha 4 beta 1,ITGA4&ITGB1
Drug Development Progress
Nombre de médicaments cliniques6
Nombre de médicaments commercialisés3
Phase de R&D la plus avancéeApproved
Alias de la cible
Integrin alpha4beta1
Contexte de la molécule
Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. Integrin alpha 4 beta 1(Alpha-4/beta-1) is receptors for fibronectin. Integrin alpha-4/beta-1 is a receptor for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1.

Integrin alpha 4 beta 1 Liste de produits

Species
  • Human(2)
  • Mouse(1)
Tag
  • His Tag(2)
  • His Tag & Avi Tag(1)
Host
  • HEK293(3)
Conjugate
  • Unconjugated(2)
  • Biotin-labeled(1)
Grade
  • RUO(3)
Low Endotoxin
  • Yes(2)
  • No(1)

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
Natalizumab biosimilar (GENERIUM Pharmaceuticals)GNR-093Phase 3 ClinicalGenerium Pharmaceuticals
Multiple Sclerosis
Details
AvicursenTV-1102; ATL/TV-1102; ATL-1102; ISIS-107248Phase 2 ClinicalIonis Pharmaceuticals Inc
Multiple Sclerosis; Muscular Dystrophy, Duchenne
Details
Alintegimod7HP349; 7-HP-349; 7HP-349Phase 2 Clinical7 Hills Pharma LLC
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chagas Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Influenza, Human; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Mismatch Repair Deficient Cancer; Neoplasm Metastasis; Neoplasms; Skin Neoplasms; Solid tumours; Tuberculosis
Details
LLP2A alendronatePhase 1 ClinicalUniversity Of California
Bone Diseases; Bone Diseases, Metabolic; Osteonecrosis; Osteoporosis
Details
ABBV-243ABBV-243Phase 1 ClinicalAbbvie Inc
Details
RBx-7796RBx-7796ClinicalSun Pharmaceutical Industries Ltd
Asthma; Rhinitis, Allergic
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
Carotegrast methylAJM-300ApprovedEa Pharma, Eisai Co LtdCarograJapanColitis, UlcerativeEa Pharma Co Ltd2022-03-28
Colitis, Ulcerative
Details
Natalizumab biosimilar (Polpharma Biologics)PB-006; DST-356A1ApprovedPolpharma Biologics SaTyrukoUnited StatesMultiple Sclerosis; Crohn DiseaseSandoz Inc2023-08-24
Crohn Disease; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting
Details
NatalizumabBG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-EApprovedBiogen Inc, Perrigo LlcTysabri, Antegran, AntegrenUnited StatesCrohn Disease; Multiple SclerosisBiogen Idec2004-11-23
Arthritis, Rheumatoid; Crohn Disease; Demyelinating Diseases; Epilepsies, Partial; Graft vs Host Disease; Ischemic Stroke; Multiple Myeloma; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myositis, Inclusion Body
Details
Customer Reviews